שווי מתואם לחוב ומזומנים VolitionRx (VNRX)

VolitionRx Limited (VNRX) is implementing AI-driven Nu.Q automated systems for biomaterial analysis. Current revenue remains volatile, as it relies on research grants and the pace of laboratory test adoption, while the Enterprise Value stands at 12.41. This price chart illustrating the changes confirms the macro-resilience of the business, whose epigenetics services are not subject to seasonal fluctuations and depend solely on regulators.

VolitionRx Limited (VNRX) is strengthening its position in the early cancer diagnostics niche through partnerships with clinics. By analyzing the Enterprise Value, an investor can determine the actual cost of acquiring the business. This metric sums the market capitalization and debt, minus existing cash reserves. For VolitionRx Limited (VNRX), this metric reflects the value of the screening infrastructure adjusted for debt load. Stable price action confirms the fundamental resilience of the asset.